Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0Q2RP
|
||||
Former ID |
DIB018534
|
||||
Drug Name |
24(S), 25-epoxycholesterol
|
||||
Synonyms |
24,25-epoxy-cholesterol
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C27H44O2
|
||||
InChI |
InChI=1S/C27H44O2/c1-17(6-11-24-25(2,3)29-24)21-9-10-22-20-8-7-18-16-19(28)12-14-26(18,4)23(20)13-15-27(21,22)5/h7,17,19-24,28H,6,8-16H2,1-5H3/t17-,19+,20+,21-,22+,23+,24+,26+,27-/m1/s1
|
||||
InChIKey |
OSENKJZWYQXHBN-XVYZBDJZSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | Oxysterols receptor LXR-beta | Target Info | Agonist | [2] | |
Oxysterols receptor LXR-alpha | Target Info | Agonist | [2] | ||
KEGG Pathway | PPAR signaling pathway | ||||
Non-alcoholic fatty liver disease (NAFLD) | |||||
Hepatitis C | |||||
Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptorrxr_vdr_pathway:RXR and RAR heterodimerization with other nuclear receptor | ||||
Reactome | Nuclear Receptor transcription pathway | ||||
WikiPathways | SREBP signalling | ||||
Nuclear ReceptorsWP299:Nuclear Receptors in Lipid Metabolism and Toxicity | |||||
Nuclear Receptors Meta-Pathway | |||||
PPAR Alpha Pathway | |||||
Liver X Receptor Pathway | |||||
Adipogenesis | |||||
SREBF and miR33 in cholesterol and lipid homeostasis | |||||
Nuclear Receptors | |||||
References | |||||
REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2751). | ||||
REF 2 | Brain endogenous liver X receptor ligands selectively promote midbrain neurogenesis. Nat Chem Biol. 2013 Feb;9(2):126-33. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.